4.84
+(+%)
Currency In USD
Address
The SchrOedinger Building
Oxford, OX4 4GE
United Kingdom of Great Britain and Northern Ireland
Phone
44 18 6581 8941
Website
Sector
Healthcare
Industry
Biotechnology
Employees
483
First IPO Date
October 01, 2021
| Name | Title | Pay | Year Born |
| Dr. David Hallett Ph.D. | Chief Scientific Officer, Interim Chief Executive Officer, Principal Executive Officer & Executive Director | 0 | 1969 |
| Mr. Ben R. Taylor | Chief Financial Officer, Chief Strategy Officer & Executive Director | 558,080 | 1977 |
| Mr. Richard Law | Chief Business Officer | 0 | N/A |
| Dr. John P. Overington Ph.D. | Chief Technology Officer | 0 | N/A |
| Dr. Marie-Louise Helena Fjallskog M.D., Ph.D. | Interim Chief Medical Officer & Clinical Development Lead | 0 | 1964 |
| Mr. Parker Moss | Executive Vice President of Corporate Development | 0 | N/A |
| Mr. Nikolaus Krall | Executive Vice President of Precision Medicine | 0 | N/A |
| Ms. Sara Sherman | Vice President of Investor Relations | 0 | N/A |
| Ms. Caroline Rowland | Chief People Officer | 0 | N/A |
| Mr. Dan Ireland | Executive Vice President of Legal & Company Secretary | 0 | N/A |
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.